Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035308 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
A Phase 3 study, sponsored by La Jolla Pharmaceutical Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT00035308: Completed Phase 3 study, sponsored by La Jolla Pharmaceutical Company.
NCT00035308 is a Phase 3 study that has completed, run by La Jolla Pharmaceutical Company. The registered enrollment target is 330 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035308, a Phase 3 study, has completed, sponsored by La Jolla Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
Interventions
- DRUG Abetimus sodium (LJP 394)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Est. Completion | 2002-12 |
| Phase | Phase 3 |
What the finished NCT00035308 record still lists
NCT00035308 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Abetimus sodium (LJP 394) is the first listed.
NCT00035308 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035308 about?
NCT00035308 is a clinical study titled "Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease". The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
What is the current status of trial NCT00035308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00035308?
The interventions under investigation include: Abetimus sodium (LJP 394) (DRUG).
Who is sponsoring clinical trial NCT00035308?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00035308's enrollment target sits among peer trials
330 1066th of 2000 higher than 927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD